Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of B7-H3CART in Children and Young Adults With Relapsed/Refractory Solid Tumors
NCT06500819Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Jul 2024
- Primary completion
- Jul 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B7H3-CART in neuroblastoma, sarcoma, osteosarcoma (OS) and 2 more, sponsored by Stanford University. Primary endpoints: Feasibility of manufacturing autologous T cells at 2 years and Maximum Tolerated Dose and Recommended Phase 2 Dose at 2 years. Started Jul 2024; status: recruiting.
02
Drugs
B7H3-CART
03
Conditions
neuroblastomasarcomaosteosarcoma (OS)Ewing sarcomaWilms' tumor
Beyond the preview
Go deeper on NCT06500819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500819.